文献速递神经免疫认知障碍与痴呆

儿童MS及其他获得性脱髓鞘综合征的血清神经丝轻链

Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes.
PubMed 文献 · Neurology · 2019-08-05

本研究纳入102例首次发作的儿童获得性脱髓鞘综合征患者和23例年龄匹配对照,检测血清与脑脊液神经丝轻链(NfL)的相关性及其与未来疾病活动的关联。结果显示脑脊液与血清NfL显著相关,基线血清NfL较高与无脑病表现患者未来临床确诊MS的风险增加相关。

要点

  • 血清与脑脊液NfL显著相关,支持血清NfL作为神经轴索损伤的外周标志物。
  • 基线血清NfL高于26.7 pg/mL与无脑病表现患者更短时间进展为临床确诊MS相关。
  • 血清NfL每增加10 pg/mL,临床确诊MS的风险比为1.09。

核心结论

  • 血清与脑脊液NfL显著相关,支持血清NfL作为神经轴索损伤的可靠外周标志物。
  • 在无脑病表现的获得性脱髓鞘综合征患者中,基线血清NfL较高与未来临床确诊MS概率增加相关。

研究设计与样本

  • 纳入102例年龄小于18岁首次中枢神经系统脱髓鞘发作的患者和23例年龄匹配对照。
  • 以临床确诊多发性硬化(CDMS)为分析终点,采用Cox回归计算风险比(HR)。

主要发现

  • 总组中脑脊液与血清NfL显著相关(ρ 0.532,p < 0.001),未来CDMS亚组中相关性更强(ρ 0.773,p < 0.001)。
  • 血清NfL在患者中高于对照(几何均值6.1 pg/mL,p < 0.001)。
  • 血清NfL最高见于伴脑病的ADS(急性播散性脑脊髓炎,n=28,100.4 pg/mL),其次为无脑病但未来CDMS者(n=40,32.5 pg/mL)和保持单相病程者(n=34,17.6 pg/mL)。
  • 基线血清NfL中位数高于26.7 pg/mL与无脑病ADS患者更短时间进展为CDMS相关(p = 0.045)。
  • 校正年龄、寡克隆带和MRI指标后,血清NfL每增加10 pg/mL,CDMS诊断的HR为1.09(p = 0.012)。

关键数值与推荐

  • 血清NfL高于中位数26.7 pg/mL作为基线阈值与无脑病ADS患者CDMS时间缩短相关。
  • 血清NfL每10 pg/mL增量对应CDMS风险HR 1.09(校正后p = 0.012)。

临床怎么用

  • 血清NfL可作为儿童ADS患者神经轴索损伤的微创外周标志物。
  • 基线血清NfL水平有助于识别无脑病表现ADS患者中未来进展为CDMS的高风险个体。

局限性

  • 仅47例(46%)患者进行了脑脊液NfL检测。
  • 研究样本量有限,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To explore the correlation between serum and CSF neurofilament light chain (NfL) and the association of NfL levels and future disease activity in pediatric patients with a first attack of acquired demyelinating syndromes (ADS). METHODS: In total, 102 children <18 years with a first attack of CNS demyelination and 23 age-matched controls were included. Clinically definite multiple sclerosis (CDMS) was set as an endpoint for analysis. CSF NfL was tested by the commercially available ELISA (UmanDiagnostics); serum NfL (sNfL) was tested with a Simoa assay. Hazard ratios (HR) were calculated with Cox regression analysis. RESULTS: Of the 102 patients, 47 (46%) were tested for CSF NfL. CSF and serum NfL correlated significantly in the total group (ρ 0.532, p < 0.001) and even more significantly in the subgroup of patients with future CDMS diagnosis (ρ 0.773, p < 0.001). sNfL was higher in patients than in controls (geometric mean 6.1 pg/mL, p < 0.001), and was highest in ADS presenting with encephalopathy (acute disseminated encephalomyelitis, n = 28, 100.4 pg/mL), followed by patients without encephalopathy (ADS-) with future CDMS diagnosis (n = 40, 32.5 pg/mL), and ADS- who remained monophasic (n = 34, 17.6 pg/mL). sNfL levels higher than a median of 26.7 pg/mL at baseline are associated with a shorter time to CDMS diagnosis in ADS- (p = 0.045). HR for CDMS diagnosis was 1.09 for each 10 pg/mL increase of sNfL, after correction for age, oligoclonal bands, and MRI measures (p = 0.012). CONCLUSION: The significant correlation between CSF and serum NfL strengthens its reliability as a peripheral marker of neuroaxonal damage. Higher sNfL levels at baseline were associated with higher probability of future CDMS diagnosis in ADS-.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Wong YYM, Bruijstens AL, Barro C, et al. Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes. Neurology. 2019. PMID: 31383792. doi:10.1212/WNL.0000000000008057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。